Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462337 | 0.88 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL3957527 | 0.87 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL3958601 | 0.84 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL23831439 | 0.84 | GRIK1 (0.80) | GRIK1GRIK2 | |
| SCHEMBL6431068 | 0.83 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL5950041 | 0.83 | GRIK1 (0.74) | GRIK1GRIK2 | |
| SCHEMBL3962344 | 0.83 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL3962742 | 0.83 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL6430905 | 0.82 | GRIK1 (1.00) | GRIK1MEN1KMT2AGRIK2 | |
| SCHEMBL3957387 | 0.82 | GRIK1 (1.00) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | claimed |
| JP-2005538152-A | — | — | 2005-12-15 | — | — | JP | claimed |
| EP-1537075-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2005-06-08 | — | — | EP | claimed |
| WO-2004022529-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1537075-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022529-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | KIT, ORAI1, CACNA1C | GRIK1 3295/4885MEN1 1915/4885KMT2A 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.